Priovant’s Brepocitinib Posts Strong Phase 2 Win in Cutaneous Sarcoidosis

The 31‑patient BEACON trial met key efficacy measures with no serious adverse events, positioning the oral TYK2/JAK1 inhibitor for a Phase 3 start in 2026 pending FDA input.

Overview

Patients on 45 mg improved by 22.3 points on the CSAMI‑A scale at Week 16 versus 0.7 for placebo (P<0.0001), with separation from placebo seen by Week 4.
All patients on 45 mg achieved at least a 10‑point CSAMI‑A improvement versus 14% on placebo, and 62% reached functional remission (CSAMI‑A <5) versus 0% on placebo.
On the Investigator’s Global Assessment, 69% on 45 mg reached Clear or Almost Clear compared with 0% on placebo (P=0.0047).
Patient‑reported outcomes improved across KSQ skin domain, Skindex‑16, and PGI‑C, with 100% on 45 mg reporting improvement on PGI‑C versus 29% on placebo.
Brepocitinib was well tolerated with no serious adverse events, the 15 mg dose also showed meaningful benefit, and Priovant plans to advance to a pivotal program in 2026 after FDA engagement.